Clinical Trials Browser

Phase 3 × Neoplasms × rovalpituzumab tesirine × Clear all

NCT03033511 2021-07-29

MERU

Phase 3 Terminated

748 enrolled 13 charts

Neoplasms, Small Cell Lung Carcinoma

NCT03334487 2018-12-26

Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Phase 3 Withdrawn

Neoplasms, Small Cell Lung Carcinoma